- Home
- UEIC vs TLSI Comparison
UEIC vs TLSI Comparison
Compare UEIC & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UEIC
- TLSI
- Stock Information
- Founded
- UEIC 1986
- TLSI 2010
- Country
- UEIC United States
- TLSI United States
- Employees
- UEIC N/A
- TLSI N/A
- Industry
- UEIC Consumer Electronics/Appliances
- TLSI Medical Specialities
- Sector
- UEIC Consumer Staples
- TLSI Health Care
- Exchange
- UEIC Nasdaq
- TLSI Nasdaq
- Market Cap
- UEIC 126.2M
- TLSI 158.0M
- IPO Year
- UEIC 1993
- TLSI N/A
- Fundamental
- Price
- UEIC $6.89
- TLSI $5.30
- Analyst Decision
- UEIC Strong Buy
- TLSI Strong Buy
- Analyst Count
- UEIC 2
- TLSI 6
- Target Price
- UEIC $14.50
- TLSI $11.75
- AVG Volume (30 Days)
- UEIC 100.8K
- TLSI 39.7K
- Earning Date
- UEIC 05-01-2025
- TLSI 03-27-2025
- Dividend Yield
- UEIC N/A
- TLSI N/A
- EPS Growth
- UEIC N/A
- TLSI N/A
- EPS
- UEIC N/A
- TLSI N/A
- Revenue
- UEIC $394,879,000.00
- TLSI $26,891,000.00
- Revenue This Year
- UEIC $3.65
- TLSI $61.29
- Revenue Next Year
- UEIC $9.05
- TLSI $53.21
- P/E Ratio
- UEIC N/A
- TLSI N/A
- Revenue Growth
- UEIC N/A
- TLSI 67.90
- 52 Week Low
- UEIC $6.77
- TLSI $3.50
- 52 Week High
- UEIC $14.20
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- UEIC 26.89
- TLSI 47.92
- Support Level
- UEIC $7.00
- TLSI $4.60
- Resistance Level
- UEIC $10.06
- TLSI $5.68
- Average True Range (ATR)
- UEIC 0.43
- TLSI 0.35
- MACD
- UEIC -0.05
- TLSI -0.09
- Stochastic Oscillator
- UEIC 8.37
- TLSI 56.00
About UEIC Universal Electronics Inc.
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.